AR-V7 Androgen Receptor Variant as a Predictor of Response to Androgen-receptor Targeting Agents Used to Treat Castration-refractory Metastatic Prostate Cancer

Büchler, Tomáš; Bobek, Vladimír; Kološtová, Katarína

doi:10.14735/amko20189

Cited by 2 publications

(1 citation statement)

References 18 publications

(33 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The results of a prospective clinical trial evaluating abiraterone in 454 patients treated in clinical practice demonstrated the median PFS 17.3 (95% CI: 14.1-19.4) months and median OS 37.3 (95% CI: 36.5 -not reached) months. There was a higher percentage of patients above 75 years old in the study and higher proportion of patients with visceral disease than in our group [22].…”

Section: Discussioncontrasting

confidence: 65%

Abiraterone and enzalutamide in the first line therapy of metastatic castration resistant prostate cancer

Al-Samsam,

Bartoš,

Šámal

et al. 2024

Rep Pract Oncol Radiother.

View full text Add to dashboard Cite

Background:The aim was to assess therapeutic outcomes and tolerance in patients with metastatic castration resistant prostate cancer (mCRPC) treated with androgen receptor targeted agents (ARTA) treatment at one oncological center in the Czech Republic. Materials and methods:Retrospective analysis of 64 patients with mCRPC treated with abiraterone (50 patients) and enzalutamide (14 patients) in the first line of this disease was conducted. Kaplan-Meier analysis was used to calculate progression free survival (PFS) and overall survival (OS). We performed a multivariate analysis of risk factors for treatment outcomes (PFS, OS) by Cox regression analysis. Results:The median follow-up was 28.4 months. The median PFS was 15.4 months [95% confidence interval (CI): 12.3-18.5], median OS was 38.2 months (95% CI: 19.9-56.5). Regression analysis demonstrated a favorable prognostic effect on PFS in patients with reduction of PSA ≥ 50 %, in patients with early reduction of prostate-specific antigen (PSA) ≥ 50% within 3 months, in patients younger than 74 years and in overall performance status (PS) 0. Regression analysis demonstrated a favorable prognostic effect on OS in patients with reduction of PSA ≥ 50 %, in patients with early reduction of PSA ≥ 50 % within 3 months and in patients with overall PS 0. Adverse effects grade 3-4 were reported in 17 (27.9%) patients in abirateron arm and in 1 (7.1%) patient in enzalutamide arm. Conclusion:The analysis of patients with mCRPC treated with ARTA in the first line showed that ARTA represents an effective and safe therapy and contributes to longer survival.

show abstract

Section: Discussioncontrasting

confidence: 65%